Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved drastically in recent years and many novel therapeu...
Main Authors: | Iván Henríquez, Mack Roach, Todd M. Morgan, Alberto Bossi, Junior A. Gómez, Oscar Abuchaibe, Felipe Couñago |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/9/1247 |
Similar Items
-
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
by: Wout Devlies, et al.
Published: (2020-11-01) -
Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Melissa Gamat-Huber, et al.
Published: (2020-09-01) -
Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01) -
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
by: Moran Gadot, et al.
Published: (2020-04-01) -
Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
by: Bram De Laere, et al.
Published: (2021-03-01)